Myomo (MYO) reported 2Q 2026 revenue growth of 21%, supported by a shift in patient acquisition toward recurring referral sources and expanded reimbursement relationships. The update suggests improving commercial traction, though no absolute revenue figure or forward guidance was provided.
Myomo (MYO) reported 2Q 2026 revenue growth of 21%, supported by a shift in patient acquisition toward recurring referral sources and expanded reimbursement relationships. The update suggests improving commercial traction, though no absolute revenue figure or forward guidance was provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
